Description
Melanocortin Research Peptides
Lyophilised Powder
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II. It is a melanocortin receptor agonist with primary activity at the MC4R and MC1R subtypes. Unlike its parent compound, PT-141 was specifically developed and investigated for its activity at central nervous system melanocortin-4 receptors (MC4R) rather than peripheral melanocortin pathways.
Published peer-reviewed research has examined PT-141’s receptor binding profile and downstream signalling at MC4R in hypothalamic and CNS tissue models. Studies have investigated its effects on central melanocortin pathway activation, including intracellular calcium mobilisation and cAMP generation in MC4R-expressing cell lines. The compound has been the subject of multiple published clinical-stage investigations (Phase II and Phase III) evaluating its pharmacokinetic profile, receptor selectivity, and central mechanism of action. PT-141’s structural modification from Melanotan II — the removal of the C-terminal amide — has been characterised in published structure-activity relationship studies as conferring a shift in receptor subtype preference.
This product is supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. It is intended exclusively for use in controlled laboratory settings by qualified researchers.
Product Specifications
| Compound | PT-141 (Bremelanotide) |
| Quantity | 10mg per vial |
| Form | Lyophilised powder |
| Purity | ?98% (verified by third-party HPLC analysis) |
| Molecular Weight | ~1,025.18 Da |
| CAS Number | 189691-06-3 |
| Appearance | White powder |
Certificate of Analysis
View CoA — Janoshik Analytical
Independent third-party testing by Janoshik Analytical (Czech Republic). Tests include HPLC purity analysis and mass spectrometry identification.
Storage Instructions
After reconstitution: Store at 2–8°C. Use within 14 days. Do not freeze once reconstituted.
